These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17142138)

  • 1. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
    Matsumoto S; Takebayashi K; Aso Y
    Metabolism; 2006 Dec; 55(12):1645-52. PubMed ID: 17142138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy.
    Takebayashi K; Matsumoto S; Aso Y; Inukai T
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2214-7. PubMed ID: 16569732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 2 diabetes mellitus coincident with pulmonary or latent tuberculosis results in modulation of adipocytokines.
    Pavan Kumar N; Nair D; Banurekha VV; Dolla C; Kumaran P; Sridhar R; Babu S
    Cytokine; 2016 Mar; 79():74-81. PubMed ID: 26771473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
    Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
    Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
    Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of aldosterone in diabetic nephropathy.
    Cha DR; Kang YS; Han SY; Jee YH; Han KH; Kim HK; Han JY; Kim YS
    Nephrology (Carlton); 2005 Oct; 10 Suppl():S37-9. PubMed ID: 16174286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
    Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
    J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus.
    Hsieh CH; He CT; Lee CH; Wu LY; Hung YJ
    Metabolism; 2007 Aug; 56(8):1087-92. PubMed ID: 17618954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
    Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
    Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.
    Xu F; Liu H; Sun Y
    Ren Fail; 2016; 38(1):157-62. PubMed ID: 26616527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.
    Takebayashi K; Suetsugu M; Wakabayashi S; Aso Y; Inukai T
    Metabolism; 2007 Apr; 56(4):451-8. PubMed ID: 17378999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Suzuki H; Fujii Y; Ito M; Yoshida Y; Okada K; Soma M
    Hypertens Res; 2012 Aug; 35(8):874-81. PubMed ID: 22592665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of aldosterone blockade in patients with diabetic nephropathy.
    Sato A; Hayashi K; Naruse M; Saruta T
    Hypertension; 2003 Jan; 41(1):64-8. PubMed ID: 12511531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats.
    Han KH; Kang YS; Han SY; Jee YH; Lee MH; Han JY; Kim HK; Kim YS; Cha DR
    Kidney Int; 2006 Jul; 70(1):111-20. PubMed ID: 16723984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.
    Kanaya AM; Wassel Fyr C; Vittinghoff E; Harris TB; Park SW; Goodpaster BH; Tylavsky F; Cummings SR
    Arch Intern Med; 2006 Feb; 166(3):350-6. PubMed ID: 16476877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
    Kato S; Maruyama S; Makino H; Wada J; Ogawa D; Uzu T; Araki H; Koya D; Kanasaki K; Oiso Y; Goto M; Nishiyama A; Kobori H; Imai E; Ando M; Matsuo S
    Clin Exp Nephrol; 2015 Dec; 19(6):1098-106. PubMed ID: 25795029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study.
    Shimizu H; Oh-I S; Tsuchiya T; Ohtani KI; Okada S; Mori M
    Diabet Med; 2006 Mar; 23(3):253-7. PubMed ID: 16492207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy.
    Momeni A; Behradmanesh MS; Kheiri S; Karami Horestani M
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):113-8. PubMed ID: 23486907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.